Hello, my name is
Peter Taylor Norman Collison,
Professor of Musculoskeletal Sciences
at the University of Oxford.
Thank you for
joining me in this Henry Stewart talk,
regarding rheumatoid arthritis.
In part one of this talk we're going
to consider the history of rheumatoid
arthritis, a presentation
of the condition, and
some of the issues around
the pathobiology of treatments, and
then we'll go on in part two of the talk
to look at approaches to therapy.
Here are my disclosures, I had the whole
research grants or have been involved
with consultational speaking for
the following pharma companies.
Let's start with a question,
what's the commonest cause of
chronic inflammatory polyarthritis?
And indeed, ask also what does
the nomenclature actually mean?
The suffix "itis" refers to inflammation,
the root "arth" actually
implies a joint hence we have
the English word articulate or
articulated with the same root and
"poly", the prefix implies many, and
in this context, we're usually
thinking about six or more joints.
So the commonest chronic inflammatory
polyarthritis is in fact rheumatoid
arthritis, with a worldwide
prevalence of around about 1%, and
the picture illustrates somebody
who has this condition, and
some of the swelling in joints is evident.
So before we come on to think about
the more recent developments in rheumatoid
arthritis, we'll start off
by considering history.
The first description of this
condition was in the 18th century, and
Garrod was the person who first
coined the term rheumatoid arthritis.
Rheumatoid by the way comes from the Greek
root "rheum", which means to flow because
the symptoms often move from one
part of the body to another.
And over the years, they've been evolving
concepts of disease definition, causation
and therapy and then we'll explore many
of these issues together, in this talk.
So what about the prevalence and
outcome of rheumatoid arthritis?